Years-long decline before final shutdown · Fatal mistake: Colombia biopharma: INVIMA (national pharma regulator) clinical trial approval took 36+ months for novel biologics. Plan Vallejo (manufacturing export tax exemption) required 70% export commitment. INVIMA biosimilar pathway was not approved until 2021. ELaboratorio (national public pharma) crowded out private biopharma in public procurement. No viable commercial biopharma market without 36-month regulatory runway.
Evaluating only BioPharCO’s profile at its peak — without knowing the outcome — the model ranked Regulation as the #1 likely cause. That’s exactly how it died.
Key Events Timeline
FOUNDING
CRISIS
SHUTDOWN
Full Analysis
Free · no account needed
Documented cause
BioPharCO built biosimilar oncology. INVIMA 36-month trial approval. Biosimilar pathway not codified until 2021. ELaboratorio dominated public procurement. 5-year runway insufficient at $12M.
Lesson
“Colombia biopharma must partner with an established multinational for regulatory pathway and distribution — a standalone Colombian biopharma company cannot fund the INVIMA timeline from venture capital.”
Failure anatomy
Collapse type
Slow Death
🐌 LOW
Hype cycle
None
Moat type
Technology
Fatal mistake
Colombia biopharma: INVIMA (national pharma regulator) clinical trial approval took 36+ months for novel biologics. Plan Vallejo (manufacturing export tax exemption) required 70% export commitment. INVIMA biosimilar pathway was not approved until 2021. ELaboratorio (national public pharma) crowded out private biopharma in public procurement. No viable commercial biopharma market without 36-month regulatory runway.